ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Upton Wraps Up Reorganization – DCCR Revamped, No Prevention Division

October 12, 1979

In Brief: FDA’s Burlington Moves to Wyeth-Ayerst; NAS Award to Beckman; Genetics Online

February 5, 1999

Kennedy Attempts To Establish Unit For All Biomedical Research Similar To Successful Cancer Panel; Administration Threatens Veto

March 15, 1974

Board Oks Construction PA Fro Breast Cancer Research Facilities

July 9, 1993

CMS Develops New Math of Medicare: Reimbursement Money for Outcomes Data.

February 4, 2005

NCI-Approved Clinical Trials

July 30, 2010